A well-known, existing specialty therapy in open distribution was challenged by the pending approval of an additional orphan indication. The brand was working to address FDA comments and concerns regarding the potential for dosing errors and a request to perform additional HF studies. Our Advisors were engaged to support the design/development of a limited distribution and channel support strategy for the new orphan indication.
Our Advisors rapidly worked with the brand and managed markets teams to:
|
|